Dunhill Financial’s Day One Biopharmaceuticals DAWN Stock Holding History

Dunhill Financial’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$6	–	1921
2025 Q4	$6	Buy	+1	New	+$8	﹤0.01%	2002

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Dunhill Financial's DAWN Position: Q1 2026 in Review

Dunhill Financial sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 1 share — an estimated $6 sold.

Dunhill Financial first reported a position in DAWN in Q4 2025 and held it in 1 quarter. The position peaked at $6 in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Dunhill Financial reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
Dunhill Financial sold 1 Day One Biopharmaceuticals share in Q1 2026, an estimated $6.
Dunhill Financial first reported a position in Day One Biopharmaceuticals in Q4 2025 and held it in 1 quarter.
Dunhill Financial's Day One Biopharmaceuticals position peaked at $6 in Q4 2025.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.